Evidence map›Paper›PMID 40823695›Full record

ReviewEpigenomics2025

The functional and therapeutic potential of epitranscriptomics in breast cancer.

Rachel L Thompson, Jennifer Lothion-Roy, Eleanor Bellows, Corinne L Woodcock, Jorja Jackson-Oxley, Maria Haque, Dhruvika Varun, Amber A Kumari, Mansour Alsaleem, Simone de Brot and 12 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epigenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rachel L ThompsonBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0009-0001-4974-0355
Jennifer Lothion-RoyBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0002-8602-7006
Eleanor BellowsBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0003-0055-8330
Corinne L WoodcockBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0001-6369-0182
Jorja Jackson-OxleyBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0009-0007-1885-6818
Maria HaqueBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0009-0009-9669-2606
Dhruvika VarunBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0002-8364-2994
Amber A KumariBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0009-0001-3851-9794
Mansour AlsaleemBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0002-7689-2493
Simone de BrotBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0003-3049-0103
Atara NtekimCollege of Medicine, Faculty of Clinical Science, University of Ibadan, Ibadan, Nigeria.ORCID 0000-0003-4830-8365
Musalwa Muyangwa-SemanovaBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0003-0030-9764
Emad RakhaSchool of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0002-5009-5525
Srinivasan MadhusudanSchool of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0002-5354-5480
Nathan ArcherSchool of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.ORCID 0000-0002-3356-6161
Rupert G FraySchool of Biosciences, University of Nottingham, Nottingham, UK.ORCID 0000-0002-3935-8945
Sheeba IrshadCancer & Pharmaceutical Sciences, King's College London & Guys & St Thomas NHS Trust, London, UK.ORCID 0000-0002-4419-7162
Richard D EmesNottingham Trent University, Nottingham, UK.ORCID 0000-0001-6855-5481
Jennie N JeyapalanBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0002-6133-224X
Catrin S RutlandBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0002-2009-4898
Nigel P MonganBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0001-5438-1126
Anna E HarrisBiodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.ORCID 0000-0003-4153-1652

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BCa) is one of the most commonly diagnosed malignancies worldwide and is clinically heterogenous. BCa is classified into distinct histopathological and molecular subtypes that inform diagnosis, treatment, and prognosis. Although therapeutic advances, particularly targeted therapies, have improved outcomes, metastatic BCa remains an unmet clinical need. In addition, treatment options remain limited especially for triple negative BCa (TNBC). There is an urgent need to develop novel approaches that can prevent, delay, or reverse disease progression in these patients. The roles of genetic and epigenetic alterations in BCa are well established. Emerging evidence highlights the dysregulation of epitranscriptomic mechanisms involving covalent RNA modifications as a contributing factor in BCa pathogenesis. Notably, recent evidence supports functional crosstalk between epigenetic and epitranscriptomic processes with potential clinical and therapeutic relevance. This review explores key epitranscriptomic RNA modifications, m

Indexed as

Breast NeoplasmsEpigenesis, GeneticRNA Processing, Post-TranscriptionalTranscriptomeBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansBiomarkers, Tumor5-methylcytosineclinical applicationsepicapomeN1-methyladenosineN6-methyladenosineN7-methylguanosineRNA methylationRNA therapeutics

Identifiers

PMID40823695
PMCPMC12490386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.